Verywell Health on MSN

How is Huntington's disease treated?

Medically reviewed by Huma Sheikh, MDKey TakeawaysThe medications approved by the Food and Drug Administration (FDA) for ...
Nature

Benign Hereditary Chorea and NKX2-1 Gene Mutations

Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...
Healio

Patients with unexplained chorea should be tested for antiphospholipid antibodies

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...
Nasdaq

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD ...
The American Journal of Managed Care

Corticosteroid Treatment Associated With Fast, Improved Outcomes in Patients With Sydenham Chorea

In a study on treatments and outcomes in patients with Sydenham chorea (SC), corticosteroids were associated with faster resolution, while antibiotics, corticosteroids, and sodium valproate were ...
Seeking Alpha

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...